CR20180163A - Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador - Google Patents

Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador

Info

Publication number
CR20180163A
CR20180163A CR20180163A CR20180163A CR20180163A CR 20180163 A CR20180163 A CR 20180163A CR 20180163 A CR20180163 A CR 20180163A CR 20180163 A CR20180163 A CR 20180163A CR 20180163 A CR20180163 A CR 20180163A
Authority
CR
Costa Rica
Prior art keywords
biespectific
stimulator
antibodies
specific
tnf
Prior art date
Application number
CR20180163A
Other languages
English (en)
Inventor
Viktor; Levitski
Koller Claudia; Ferrara
Christina; Claus
Pablo Umaña
Maria; Amann
Peter; Bruenker
Sandra; Grau-Richards
Christian; Klein
Ralf; Hosse
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20180163A publication Critical patent/CR20180163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Abstract

La invención se refiere a moléculas de unión a antígeno biespecíficas novedosas que comprende (a) al menos un resto capaz de unirse específicamente a un antígeno de célula diana, (b) al menos un resto capaz de unirse específicamente a un miembro de la familia del receptor TNF coestimulador, y (c) un dominio Fc compuesto de una primera y una segunda subunidad capaz de asociarse establemente, y a métodos para producir estas moléculas y a métodos para usar las mismas
CR20180163A 2015-10-02 2016-09-29 Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador CR20180163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15188095 2015-10-02
EP16170363 2016-05-19
PCT/EP2016/073185 WO2017055398A2 (en) 2015-10-02 2016-09-29 Bispecific antibodies specific for a costimulatory tnf receptor

Publications (1)

Publication Number Publication Date
CR20180163A true CR20180163A (es) 2018-05-25

Family

ID=57018141

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180163A CR20180163A (es) 2015-10-02 2016-09-29 Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador

Country Status (21)

Country Link
US (2) US10526413B2 (es)
EP (1) EP3356403A2 (es)
JP (2) JP7034066B2 (es)
KR (1) KR20180053674A (es)
CN (3) CN115746143A (es)
AU (1) AU2016329120B2 (es)
BR (1) BR112018002570A2 (es)
CA (1) CA2992863A1 (es)
CL (1) CL2018000390A1 (es)
CO (1) CO2018000710A2 (es)
CR (1) CR20180163A (es)
IL (1) IL257112A (es)
MA (1) MA43017A (es)
MX (2) MX2018003820A (es)
PE (2) PE20240096A1 (es)
PH (1) PH12018500636A1 (es)
RU (1) RU2761115C1 (es)
TW (2) TWI811982B (es)
UA (1) UA125962C2 (es)
WO (1) WO2017055398A2 (es)
ZA (1) ZA201800535B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
KR20160044060A (ko) * 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
MX2017006250A (es) 2014-11-14 2017-11-17 Hoffmann La Roche Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf.
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA2992863A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
EP3484922A1 (en) 2016-07-14 2019-05-22 Genmab A/S Multispecific antibodies against cd40 and cd137
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
AU2017332452B2 (en) 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
MA47200A (fr) 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3601345A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
CN111051344B (zh) 2017-06-08 2023-10-27 黑带医疗有限公司 Cd38调节抗体
US20180371088A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
US11542338B2 (en) * 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
SG11202003280SA (en) 2017-10-24 2020-05-28 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+ cells
JP7098725B2 (ja) 2017-11-01 2022-07-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性２＋１コントースボディ
EP3704155A2 (en) * 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN111655730A (zh) * 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 包含与lag3结合的抗原结合位点的双特异性抗体
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
SG11202007945UA (en) * 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
KR20210005169A (ko) 2018-04-25 2021-01-13 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
CN112424228A (zh) * 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CN112789294A (zh) * 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
EP3830124A1 (en) * 2018-08-01 2021-06-09 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
CN112654641A (zh) * 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
AU2019355252A1 (en) 2018-10-01 2021-04-01 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-FAP clone 212
BR112021012101A2 (pt) 2018-12-21 2021-09-08 F. Hoffmann-La Roche Ag Moléculas de ligação ao antígeno agonístico cd28 biespecífico, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula, composição farmacêutica, uso da molécula e método de inibição do crescimento de células tumorais
CN110452294B (zh) * 2019-08-06 2020-08-07 复旦大学 五种铰链区及其嵌合抗原受体和免疫细胞
EP4048309A4 (en) 2019-10-24 2024-02-21 Prometheus Biosciences Inc HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES
EP4100054A1 (en) * 2020-02-07 2022-12-14 Washington University Antibodies protective against influenza b
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2021226204A2 (en) * 2020-05-05 2021-11-11 Oncorus, Inc. Anti-dll3 antibodies and methods of use
BR112022021447A2 (pt) 2020-05-19 2022-12-13 Boehringer Ingelheim Int Moléculas de ligação para o tratamento de câncer
AR128031A1 (es) * 2021-12-20 2024-03-20 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
KR20230119856A (ko) 2022-02-08 2023-08-16 연세대학교 산학협력단 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1060247T3 (da) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001025454A2 (en) 1999-10-04 2001-04-12 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
JP4936299B2 (ja) 2000-08-21 2012-05-23 メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ 磁場方向検出センサ
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005003156A1 (en) 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
SI2380911T1 (en) 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2366717A3 (en) 2004-10-29 2011-12-14 University of Southern California Combination Cancer Immunotherapy with Co-Stimulatory Molecules
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
ES2605380T3 (es) 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
BRPI0820875B1 (pt) 2007-12-14 2021-10-19 Bristol-Myers Squibb Company Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX350962B (es) 2008-01-07 2017-09-27 Amgen Inc Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
PE20120211A1 (es) 2009-02-17 2012-03-24 Ucb Pharma Sa Anticuerpos que tienen especificidad por ox40 humana
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
JP5695059B2 (ja) 2009-09-29 2015-04-01 ロシュ グリクアート アーゲー 二重特異性デス受容体アゴニスト抗体
JP5950824B2 (ja) 2009-12-07 2016-07-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗腫瘍抗体療法を増強するための方法
WO2012002006A1 (ja) 2010-06-29 2012-01-05 コニカミノルタエムジー株式会社 超音波診断装置及びプログラム
PT2603530T (pt) 2010-08-13 2018-01-09 Roche Glycart Ag Anticorpos anti-fap e métodos de utilização
NZ629913A (en) 2010-08-23 2016-01-29 Univ Texas Anti-ox40 antibodies and methods of using the same
SI3489255T1 (sl) 2011-02-10 2021-11-30 Roche Glycart Ag Mutantni polipeptidi interlevkina-2
AU2012227883A1 (en) 2011-03-17 2013-10-24 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012130831A1 (en) * 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN107915775B (zh) 2011-07-11 2022-07-12 伊克诺斯科学公司 结合ox40的抗体及其用途
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
KR101685262B1 (ko) 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
EP2747781B1 (en) * 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
ES2628075T3 (es) * 2011-12-19 2017-08-01 Synimmune Gmbh Molécula de anticuerpo biespecífica
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
EP3489254B9 (en) 2012-04-30 2022-12-21 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
KR20150038012A (ko) 2012-08-08 2015-04-08 로슈 글리카트 아게 인터루킨-10 융합 단백질 및 그의 용도
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US9226938B2 (en) 2013-03-14 2016-01-05 RMG Rehabilitation Management Group, LP Combinatorial therapy for treatment of osteoarthritis of the knee
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
MX2015014538A (es) 2013-05-07 2016-02-05 Hoffmann La Roche Moleculas de union a antigenos trimericas.
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JP2017507931A (ja) 2014-02-05 2017-03-23 シーダーズ−サイナイ メディカル センター がん及び感染症の治療方法並びに治療用組成物
RU2016135788A (ru) 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
SI3126394T1 (sl) 2014-03-31 2020-01-31 F. Hoffmann-La Roche Ag Protitelesa proti OX40 in postopki uporabe
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
CA2948054A1 (en) 2014-04-03 2015-10-08 Augusta University Research Institute, Inc. Methods for enhancing the efficacy of a tumor-directed immune response
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
EP3204412B1 (en) 2014-10-08 2020-08-19 F.Hoffmann-La Roche Ag Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160161485A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
CA2966507A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
MX2017005929A (es) 2014-11-06 2017-11-20 Genentech Inc Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
JP2018500384A (ja) 2014-11-11 2018-01-11 メディミューン リミテッド 腫瘍形成を治療するための治療の組合せ
MX2017006250A (es) 2014-11-14 2017-11-17 Hoffmann La Roche Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf.
BR112017010198A2 (pt) 2014-11-17 2017-12-26 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
CA2994346A1 (en) 2015-08-12 2017-02-16 Medimmune Limited Gitrl fusion proteins and uses thereof
CA2992863A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法

Also Published As

Publication number Publication date
AU2016329120A1 (en) 2018-02-15
MX2018003820A (es) 2018-12-10
MA43017A (fr) 2018-08-08
TW201718645A (zh) 2017-06-01
CL2018000390A1 (es) 2018-07-06
EP3356403A2 (en) 2018-08-08
TWI757252B (zh) 2022-03-11
CN115746143A (zh) 2023-03-07
MX2023006482A (es) 2023-06-20
IL257112A (en) 2018-03-29
TWI811982B (zh) 2023-08-11
JP2022088367A (ja) 2022-06-14
JP7034066B2 (ja) 2022-03-11
CA2992863A1 (en) 2017-04-06
JP7386911B2 (ja) 2023-11-27
CN108602887B (zh) 2022-06-21
PH12018500636A1 (en) 2018-09-24
CN108602887A (zh) 2018-09-28
UA125962C2 (uk) 2022-07-20
CO2018000710A2 (es) 2018-04-10
AU2016329120B2 (en) 2023-04-13
KR20180053674A (ko) 2018-05-23
WO2017055398A3 (en) 2017-05-11
BR112018002570A2 (pt) 2018-10-16
ZA201800535B (en) 2018-12-19
TW202221040A (zh) 2022-06-01
US20200071411A1 (en) 2020-03-05
CN115594765A (zh) 2023-01-13
WO2017055398A2 (en) 2017-04-06
PE20240096A1 (es) 2024-01-18
RU2761115C1 (ru) 2021-12-06
PE20180950A1 (es) 2018-06-11
JP2018535662A (ja) 2018-12-06
US20170114141A1 (en) 2017-04-27
US10526413B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
CR20180163A (es) Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador
CL2018000461A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador.
CO2019007046A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CO2017006740A2 (es) Anticuerpos anti–cd79b
CL2017001660A1 (es) Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de motivo inhibidor de inmunorreceptor basado en tirosina (tigit)
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
AR105266A1 (es) Anticuerpos de unión a tau y sus fragmentos enlazantes
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
BR112016014731A2 (pt) Anticorpos anti-baff
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
CL2017002614A1 (es) Método para la purificación de proteínas
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
CR20190193A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
AR104923A1 (es) SPODOPTERA FRUGIPERDA RESISTENTE A Vip3A
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение